Navigation Links
Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
Date:12/17/2008

NEW YORK (Dec. 17, 2008) The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect.

The work by researchers at Columbia University Medical Center could potentially improve outcomes in diabetics who get stents, they say. Though drug-eluting stents reduce the chance coronary arteries will become blocked again, clogged stents are still more common in diabetic patients than in the general population. About 250,000 Americans with diabetes receive drug-eluting stents every year.

A hormone commonly associated with obesity leptin may be partly responsible, according to recently published research in the Proceedings of the National Academy of Sciences by Andrew Marks, M.D., chair of physiology & cellular biophysics and Clyde and Helen Wu Professor of Molecular Cardiology, and Steven Marx, M.D., associate professor of medicine and pharmacology. The study found that leptin, at the elevated concentrations frequently found in patients with diabetes, stimulates the growth of cells responsible for clogging the stents in mice, even in the presence of sirolimus, a drug used in many stents to prevent cell growth.

The same mouse study also identified a drug a PI3kinase inhibitor that counteracts the effect of leptin on cell growth. If added to current drug-eluting stents, such a drug may further reduce reclogging rates in patients with diabetes to the single digit rates seen in other patients. An improved stent could significantly reduce the numbers of patients who eventually need coronary bypass surgery after their stents become severely obstructed.


'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
212-305-0820
Columbia University Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Cost of Hospital Cardiac Care on the Rise
2. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
3. Hormone therapy for prostate cancer does not appear to increase cardiac deaths
4. ICON Medical Imaging Launches New Cardiac Echocardiography Analysis Software
5. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
6. Lung Disease Tied to Increased Risk for Cardiac Events
7. AGA Medical Receives European CE Mark Approval for AMPLATZER(R) Cardiac Plug
8. Another Study Warns of Risk From Cardiac Surgery Drug
9. Radiological Society of North America research: Cancer risk from cardiac CT overstated
10. Risk of death may be higher with drug commonly used during cardiac surgery
11. Large study illustrates cardiac CT can effectively assess coronary artery disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... 2017 Tempus, a technology company focused ... Hospitals Seidman Cancer Center have joined together to ... advanced molecular analysis and clinical decision support tools ... providers. As part of the ... sequencing and analysis for ovarian and triple negative ...
Breaking Medicine Technology: